Work

Ultrasensitive MRD Profiling Predicts Outcomes in DLBCL after Frontline Therapy with Tafasitamab in Combination with Lenalidomide and R-CHOP

Year: 2022

Type: article

Source: Blood

DOI: 10.1182/blood-2022-168378

Authors: David M. Kurtz, Gregory J. Hogan, Andre Schultz, Katerina Kopeckova, Christian Kuffer, Derek Blair, Steve Wagner, Sandra Close, Maximilian Diehn, Jacob J. Chabon, Ash A. Alizadeh, Jason Westin

Institutions: Stanford University, Charles University, University Hospital in Motol, MorphoSys (Germany), Stanford Medicine, The University of Texas MD Anderson Cancer Center

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4310106245

FWCI: 0.141

Cites:

Cited by: 1

Related to: 10